Replies to post #4793 on Keep It Quick Reviews

[PoemStone]

PPHM. Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2013 Financial Results and Recent Developments
Interim Data Show Doubling of Median Overall Survival in Bavituximab-Treated Patients from Double-Blind, Placebo-Controlled Phase II Trial in Second-Line Non-Small Cell Lung Cancer; Recent Data Strongly Support Advancing Bavituximab Program Into Phase III Clinical Development
http://finance.yahoo.com/news/peregrine-pharmaceuticals-reports-first-quarter-130611753.html

http://stockcharts.com/c-sc/sc?s=PPHM&p=D&yr=0&mn=4&dy=0&i=t43471744651&r=1347309948085